Form 4: Immunome Inc. Insider Trades: CMO Sells Shares

Immunome Inc. Chief Medical Officer Robert Lechleider reported transactions involving the sale of common stock and the acquisition of stock options.

Summary

• Robert Lechleider, Chief Medical Officer of Immunome Inc., engaged in several transactions on July 2, 2026.
• He acquired 55,000 shares of common stock at a price of $8.73 per share.
• Concurrently, he disposed of a total of 55,000 shares of common stock through multiple sales.
• These sales occurred at weighted average prices ranging from $21.95 to $23.44 per share.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on March 26, 2026.
• Following these transactions, Lechleider beneficially owns 48,091 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, despite the use of a 10b5-1 plan.

Positives

• Acquisition of 55,000 common stock shares at a favorable price of $8.73, potentially indicating confidence in the company's long-term prospects.
• The sales were conducted under a pre-established Rule 10b5-1 trading plan, suggesting a structured and non-insider-trading-related approach to portfolio management.

Negatives

• Significant sale of 55,000 shares of common stock by a key executive (Chief Medical Officer).
• The sale price of the disposed shares ($21.95 to $23.44) is substantially higher than the acquisition price of the newly acquired shares ($8.73), indicating a realized profit for the executive.

Risks

• Potential negative market perception due to a senior executive selling a significant number of shares, which could be interpreted as a lack of confidence in the company's immediate future.
• The Rule 10b5-1 plan, while providing a defense against insider trading allegations, still involves the disposal of company stock by management.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. The transactions reported are related to insider stock activity.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
• Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the Issuer, or any security holder of the Issuer.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The activity reported here, involving both acquisition and disposition of shares by a Chief Medical Officer under a 10b5-1 plan, is common for executives managing their personal portfolios while adhering to regulatory requirements. The significant difference between the acquisition price of new shares and the sale price of existing shares highlights potential personal financial gains.

Stakeholder Impact

• Shareholders may view the sale of shares by a senior executive with some concern, potentially impacting short-term stock sentiment.
• Employees may interpret the executive's stock sales as a signal, though the 10b5-1 plan mitigates concerns about insider trading.

Next Steps

• The Rule 10b5-1 trading plan will continue to govern future transactions as per its terms.
• Full information regarding the number of shares sold at each separate price will be provided upon request.

Key Dates

Recommendation

The filing reports insider transactions, including both the acquisition of shares at a lower price and the sale of shares at a higher price under a Rule 10b5-1 plan. While the sale by a key executive could be a slight negative signal, the structured nature of the sale via a pre-defined plan and the acquisition of new shares suggest a balanced approach to personal financial management rather than a strong negative outlook on the company. Therefore, a 'hold' recommendation is appropriate, pending further company performance updates.

Keywords

Form 4, Insider Trading, Stock Options, Common Stock, Rule 10b5-1, Beneficial Ownership, Immunome Inc., IMNM, Robert Lechleider, Chief Medical Officer